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Introduction
Fungal infections are commonly neglected during differential
diagnosis on clinical care. However, they should be considered in
all patients with chronic sinusitis because they affect significant
numbers of patients. Fungal infections of the sinuses have
recently been attributed to most cases of chronic rhinosinusitis,
although supporting evidence is still controversial. Most fungal
sinus infections are benign or noninvasive, except when they
occur in individuals who are immunocompromised [20, 21].
Invasive fungal infections in immunocompetent individuals do
occur [1] and this subset of patients should not be overlooked.
A review of the literature and presentation of 4 clinical cases
of fungal rhinosinusitis (FRS) are presented in this article.

4 Case Reports
Case 1 – Scopulariopsis
A 54-year-old male smoker with a history of multiple traumatic
events to the nose presented to the clinic with chronic facial pain
with pressure and a series of 6 acute sinus exacerbations occurring
over 11 months, requiring antibiotic therapy. The patient claimed
right-sided facial pain/pressure and foul-smelling yellow
discharge along with fever and chills. He also reported chronic
itchy, watery eyes and intermittent rhinorrhea and current
treatment with nasal steroid spray, saline nasal irrigation,
and a decongestant. His rhinological exam demonstrated no
external ecchymosis, diffuse mild erythema of the midline
septum, which deviated slightly to the right and an exudate
within the middle meatus, bilaterally, with thick secretions.
The mucosa showed no polypoid degeneration. Radiologically,
CT of the sinuses showed extensive chronic sinusitis involving
primarily the right maxillary sinus but also extending into the
right side of the ethmoids and frontal sinus towards the right
side which was completely opacified, suggesting inflammation.
There was only minimal mucosal thickening of the floor of the
left maxillary sinus. The medial wall of the right maxillary sinus
was absent but demonstrated an amorphous high attenuation
material that was suspicious for mycetoma. The right ethmoid
conchae were markedly attenuated to absent. A soft tissue

Figure 1.
A.
Scopulariopsis sp. in sinus biopsy, 400X, GMS
stain. B. Flat sided, door-knob shaped echinulate spores (arrow),
1000X, Grocott’s methenamine silver (GMS) stain.
C-D Scopulariopsis grown on Sabouraud dextrose agar (SABDX); C. Colony at 5 days, incubated at 30°C. D. Lactophenol cotton blue stain
(LPBC), 400X, showing chains of flat sided echinulate spores.

density was present that extended into the right frontal ethmoidal
recess and slightly into the right side of the frontal sinus. Bilateral
endoscopic ethmoidectomy was performed with removal of the
right maxillary sinus contents which were sent to pathology. The
patient’s complete blood count was normal. Pathology revealed
benign respiratory epithelium covered mucosa with marked
acute and chronic nonspecific inflammation with focal erosion
and numerous fungal microorganisms. A microbiologist consult
revealed that the fungal morphology seen in the specimen was
consistent with Scopulariopsis [2]. Numerous clusters of “door
knob” shaped spiny conidia were evident (Fig. 1). Conidia were
present singularly, and in chains, characteristic of this mold.
Scopulariopsis species are keratinophilic and are most
commonly associated with onychomycosis; however, more
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Figure 2. A. Fungus ball in sinus biopsy, 100X, GMS stain.; B. Cunninghamella showing ribbon like, aseptate, hyphae (arrows),
1000X, GMS stain.; C. Columella and fruiting head of Cunninghamella, in sinus biopsy, 400X, GMS stain.; D. Round, echinulate spores
of Cunninghamella (arrows), 1000X, GMS stain.; E. Typical fruiting head of Cunninghamella grown on SABDX, LPCB stain, 1000X.; F.
Echinulate sporangiola, LPCB stain, 2000X.

recently there have been some reports of invasive infections. Of
these, about 90% are associated with one of the following risk
factors: AIDS, organ transplantation, corticosteroid therapy,
peritoneal dialysis, surgery, cardiac disease, and trauma.
Scopulariopsis is a large genus of saprophytic organisms found
mostly in soil, but frequently isolated from food, paper, and
other materials [3]. Within the genus are members of both
hyalohyphomycoses and phaeohyphomycoses. Of the hyaline
species, S. brevicaulis is responsible for causing most of human
infections while S. candidum and S. acremonium have also been
reported to cause disease in humans [4]. The organism has been
reported as a cause of rhinosinusitis [2,4,5,6,7]. The pathological
diagnosis of Scopulariopsis can be made from the characteristic
conidial morphology since there are few fungi that resemble
these microorganisms. However, the organism is highly
cultivable and grows on various mycology media commonly
found in the clinical laboratory. In this case, removal of the
infected material was sufficient to resolve the infection without
antifungal therapy. The patient improved and in a 2-year followup, he was healthy without recurrence of symptoms or infection.
Case 2 – Cunninghamella
A 67-year-old male smoker with a history of insulin dependent
diabetes mellitus and hypertension, presented to evaluation at
the ENT clinics for nasal congestion. His symptoms began 25
years ago with right side nasal polyps requiring polypectomy
at that time. He stated that recently the nasal congestion was
worse to the point he could not use his CPAP machine. He was
taking Fluticasone without any improvement. No facial pain or
pressure was identified at physical examination. A CT of the
sinus was performed with a descriptive polypoid soft tissue
density involving the right nasal cavity adjacent to the midline
turbinate, which was concerning for a nasal polyp. A significant
soft tissue density involving the base of the left maxillary sinus
with central hyper density including speckled calcified densities
indicated that could represent fungal infection. After this finding
he went to surgery and a bilateral anterior ethmoidectomy with
right side polypectomy was performed. Pathology reported
numerous of fungal hyphae morphologically consistent with
Zygomycetes. A Microbiologist consult was obtained. The
fungus was identified from the tissue sections as most consistent
with Cunninghamella. The organism showed aseptate ribbonlike hyphae, with a vesicle supporting multiple denticles giving

rise to echinulate sporangiola (spores) (Fig. 2).
Cunninghamella, is a saprobic fungus commonly found in the
soil of temperate climates. It’s a rare cause of zygomycosis in
humans often associated with trauma and immunosuppression.
[8]. The genus Cunninghamella in the order of Mucorales
encompasses filamentous fungi that are inhabitants of soil and
other environments and are common laboratory contaminants.
C. bertholletiae is the only member of the genus documented to
cause human infections [9].
Case 3 – Blastomycosis
A 55-year-old male smoker with a history of diabetes mellitus
and hypertension, presented with a right sided maxillary and
ethmoid sinusitis and preseptal cellulitis. His symptoms began
3 months prior, and consisted of right orbital pain and pressure,
headache, with a white to yellow drainage from the right nares.
A CT of the chest was performed which showed a right hilar
mass. He had an elevated white cell count of 19,400/mm3.
A transbronchial lung biopsy and endobronchial ultrasound
biopsy were performed but both showed only inflammatory
tissue. A bronchial brush specimen subsequently yielded
negative microbiology cultures. Treatment with nasal rinses,
corticosteroid spray, and antibiotics were at first helpful but
soon, earlier symptoms returned. Two months later, the patient
returned with progressive fevers, chills, night sweats, posterior
headache, and weight loss with continued right sided facial
pain and drainage from the right nares. He denied any neck
stiffness and had no other complaints. The patient underwent
two right nasal septum biopsies which were sent to pathology
and microbiology. He was initially started on fluconazole until
laboratory results from the biopsy were completed. The right
nasal septum biopsy showed yeasts, present in respiratory
mucosa with severe-acute, chronic, and granulomatous
inflammation, with necrosis. A right lateral nasal vestibule
lesion biopsy showed squamous epithelium-lined mucosa
with severe acute, chronic, and granulomatous inflammation,
ulceration, and epithelial marked hyperplasia. Pathology
obtained a microbiologist consult which identified the yeast
as broad base budding yeast cells 10-20 µm in diameter, with
thickened cell wall, and the absence of hyphae or pseudohyphae,
most consistent with Blastomyces dermatitidis (Fig. 3).
Microbiology fungal and mycobacterial stains were all negative
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not at 55°C. Because microscopic morphology was inconsistent
with Aspergillus, the isolate was referred to the University
of Texas Health, San Antonio Department of Pathology and
Laboratory Medicine, Fungus Testing Laboratory, San Antonio,
Texas. Phenotypic characterization and DNA sequencing of the
targets, ITS, D1/D2, TUB and CAL, identified the isolate as A.
fumigatus. Their lab also reported susceptibility testing results
of amphotericin B (MIC =0.5 µg/ml), fluconazole (MIC >64 µg/
ml), itraconazole (MIC =0.5 µg/ml), and isavuconazole (MIC
=0.5 µg/ml) in accordance with CLSI M38-A2 document [12].

Figure 3. Blastomyces dermatitidis. A. B. dermatitidis in sinus biopsy (arrows), 100X, GMS stain, bar=200µm; B. B. dermatitidis in sinus biopsy,
1000X, GMS stain, bar= 20µm; C. B. dermatitidis in sinus biopsy showing
broad base budding yeast cells, 1500X, hematoxylin and eosin (H&E)
stain; D. B. dermatitidis in sinus biopsy showing thickened cell wall of two
yeast cells, 2000X, H&E stain.

and cultures remained negative at five weeks. An infectious
disease consult was immediately obtained, and the patient was
started on itraconazole therapy for blastomycosis. Continued
follow-up visits were scheduled along with CT of the head to rule
out cerebral abscess.
Blastomyces dermatitidis is another fungus unique to different
geographical areas which may find a focal niche in the sinuses
and cause chronic invasive fungal rhinosinusitus. The dimorphic
fungus typically exists in the warm, moist soil of wooden areas
ricing in organ debris. Regions of Wisconsin and Tennessee are
highly endemic for blastomycosis [10]. Mostly, patients infected
with B. dermatitidis develop asymptomatic illness. This fungus
has the potential to affect bones. A three-decade survey of
skeletal blastomycosis at a United States Medical Center
revealed 31 cases; of those, 7(23%) showed skull and facial bone
involvement [10].
Case 4 – A. fumigatus
A 53-year-old, immunocompetent, white male with a 35-year
history of allergic rhinitis, sinusitis, and septoplasty performed
26 years ago for a deviated septum, presented to the emergency
department with increased nasal drainage over several weeks,
and a feeling of sinus pressure and regular headaches on the
right side, with no fevers but intermittent chills. He was given
two weeks of amoxicillin-clavulanic acid along with a nasal
decongestant and discharged. The patient returned twelve
days later with continued symptoms of right-sinus pain and
nasal discharge. A CT scan revealed complete opacification of
the right maxillary sinus with a soft tissue mass extending in
to the right side of the ethmoid air cells and towards the right
frontoethmoidal recess. There were also findings to suggest
changes of chronic right maxillary sinusitis with osteitis of
the other walls of the right maxillary sinus. Endoscopic sinus
surgery was performed and a biopsy of a suspected “fungal
ball” from the right sinus was sent to microbiology for culture.
Bacteriology recovered Escherichia coli, ampicillin resistant.
Mycology recovered on the sixth day of incubation, a white-tolight-green mold from which vesicles were produced from single,
broad, conidiophores (lacking rounded vesicles) along septate
hyphae (Fig. 4). MALDI-TOF was performed on the isolate by
the method of De Carolis et. al. [11] using the Bruker Daltonics
filamentous fungi library v.1.0, which yielded Aspergillus
fumigatus, log scores of 2.09, 1.79, and 1.73. The mold grew on
brain heart infusion -5% sheep blood agar at 30°C, and 45°C, but

Due to this atypical morphology for A. fumigatus, the possibility
that this isolate was its anamorph, Neosartorya, we reviewed
the previously published morphological characteristics of
Aspergillus section Fumigati and its teleomorph Neosartorya
[13]. The closest matching microscopic morphological features
were similar with A. unilateralis. Microscopically, our isolate
failed to demonstrate the characteristic rounded “aspergilli
vesicle” but instead showed a segmented conidiophore with
a central elongated vesicle (Fig. 4, C-D) with a central
enlarged phialide and secondary smaller phialides produced
on metulae. We noted that single-opposing conidiophores were
sometimes produced at right angles along the hyphae, similar
with those shown in Fig. 4C. The colonial morphology of our
isolate was dissimilar to A. unilateralis. The colony surface
remained white for several days, developing only light mint
green coloration toward the center of the colony whereas A.
unilateralis is fully green. The reverse morphology remained
white as opposed to a dark, black reverse for A. unilateralis.
Balajee et. al. [14] reported that the genus Aspergillus presents
numerous difficulties for morphological identification. Some
species exhibit slow sporulation and aberrant conidiophore
formation, thus requiring DNA sequence-based identification.
Thus, multiple genes such as found in ribosomal DNA regions
ITS and the ribosomal subunit D1-D2, as well as structural
genes of β-tubulin (TUB) and the calmodulin (CAL) genes
must be used to segregate species within aspergilli. Despite
the value of gene sequencing, there is no consensus as to the
genes that can be used to specifically identify the aspergilli to
species. Growth studies at various temperatures and electron
microscopic analyses of conidia morphology are still needed to
fully characterize these fungi. Since our clinical laboratory still
relies primarily on morphological/physiological identification,
we could not identify this isolate without the aid of MALDITOF and gene sequencing analysis. Unfortunately, this process
took 10 weeks to complete. This demonstrates the complexity
involved in the final diagnosis and subsequent reporting of
important clinical information related to the treatment of FRS.

Clinical definitions, manifestations and
epidemiology overview
The burden of FRS in the United States is not clearly defined.
However, there is a growing consensus that fungal infections
worldwide are increasing as certain at-risk populations are
demonstrating increased survival time [15]. Generally, at
risk populations for invasive fungal disease are those who
are immunosuppressed for some reason like age, multiple
underlying comorbidities, diabetes, malignancy, HIV, or
receipt of immunosuppressive agents [16]. However, reports
highlighting outbreaks following natural disasters or antecedent
trauma in healthy adult populations demonstrate the wide array
of potentially affected hosts [17].
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Figure 4. A. fumigatus grown on SABDX, at 30°C. A. 14-day old colony; B. LPCB stain, 400X, bar = 50µm; C. LPCB stain, 1,000X,
showing multi-septate, broad conidiophores ending in a central elongated vesicle with an enlarged phialide with cup shaped collaret.
Secondary conidiophores were often produced from the vesicle; D-F. LPCB stain, 1,500X, showing multi-septate, broad conidiophores
ending in a central elongated vesicle with an enlarged phialide having a cup shaped collaret and release of a terminal conidium
(flat at the base), and primary/secondary metulae terminating in phialides (arrows) with dark collarets and chains of round conidia.

Fungi are ubiquitous in the environment and can colonize the
upper respiratory tract mucosa when fungal spores are inhaled.
In people with normal immune function, once inhaled the
fungal growth is kept in check. With impaired host immunity,
fungi can invade host mucosa and cause invasive disease [18].
FRS comprises a spectrum on disease process, which varies
in clinical presentation, histologic appearance, and biological
significance. FRS can be acute (aggressive; symptoms <30
days), subacute (symptoms 30-90 days), and chronic (indolent;
symptoms >90 days) [19].
Clinically it could be classified as non-invasive or invasive.
Assessing the viability of the host immune system is central to
correctly differentiating and managing FRS. Immunity is the key
predisposing factor for fungal invasion of the sinuses and must
be considered for all FRS patients. Presumably, fungi are unable
to penetrate the epithelial layer when the immune system is
functioning normally. Fungal protease activation of epithelial
cells can elicit increased cytokine production and the subsequent
migration of inflammatory cells, including eosinophils which
migrate through the barrier epithelial cells in response to fungi
present [20]. Suppression of the immune system, such as from
diabetes mellitus, chemotherapy, or corticosteroids, creates a
condition in which fungi can penetrate normal mucosa barriers
and invade host tissues [21]. Non-invasive rhinosinusitis
includes: saprophytic fungal infection, fungal ball (FB), and
allergic fungal rhinosinusitis (AFRS). The invasive forms
include acute, chronic, and chronic granulomatous.

Non-invasive rhinosinusitis
AFRS represents a hypersensitive response of a competent
immune system to fungal elements. The pathogenesis could
be explained in part through IgE-mediated-(type 1) reaction to
fungal species trapped in sinonasal mucus. It has been shown
that fungi induce the production of eosinophil attracting Th2
cytokines hence, large amount of mucin is produced due allergic
inflammation [19]. The clinical presentation described includes
nasal congestion, facial pain and pressure, nasal discharge, and
diminished olfaction. Epidemiologically patients are younger,
more likely male, living in warm and humid climates such as

southern and southeastern United States, India and Middle
East. Most individuals have a history of atopy including allergic
rhinitis and/or asthma [19].
The FB is described as a dense accumulation of fungal elements
within a single sinus. The sinus most common affected is the
maxillary sinus, followed by the sphenoid sinus and unlikely
with the ethmoid of frontal sinus. These are more common
in normally functioning immune system, and more common
in middle-age women. Previously in the literature the FB was
described as “mycetoma” or “aspergilloma”. FB rarely yield
positive fungal cultures; however, Aspergillus spp. are the most
commonly isolated pathogen [19].
Saprophytic fungal infestation describes fungal colonization
of the sinonasal tract usually after a surgical procedure or a
traumatic event. Subsequent inflammation of the sinonasal
mucosa follows, and infection of the surface mucosa occurs
without tissue invasion [19]. Nasal crust can become colonized
by an extensive collection of fungi. This provides an environment
for fungal replication and nearby mucosa is usually unaffected.
Hoggard et.al. [20], reported that from one neonatal study
where nasal mucus specimens were examined, 94% of infants
yielded positive fungal cultures within the first 4 month of life.
This led them to suggest that fungi are normal constituents of
the sinonasal tract. This poses the basis of our case 1 (above)
which may have initially been colonizing sinonasal flora. The
genus of Scopulariopsis is one of the most common saprophytic
filamentous fungi [2]. Invasive disease evolution is very rare;
when present it’s associated mainly with immunocompromised
patients.

Categories of Invasive FRS
Acute invasive FRS should be suspected in immunocompromised,
particularly those on chemotherapy or bone morrow transplant,
or uncontrolled diabetic patients with acute sinusitis. It
may also occur in individuals on therapy with chronic oral
corticosteroids. The presentation of the symptoms occurs in
less than four weeks. It has indolent clinical presentation like
nasal congestion, drainage, facial pain/pressure. As the disease
advances, the patient can develop fever, epistaxis, and extension
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into to the orbit causing proptosis, ophthalmoplegia, and a
decreased visual acuity. With eventual dissemination of the
disease bone erosion may occur. Often diabetics, especially those
with diabetic ketoacidosis experience invasive fungal infection of
this type. This is frequently caused by the fungi belonging to the
order of Zygomycetes, such as Rhizopus, Rhizomucor, Absidia,
and Mucor. In patients with severe neutropenia, Aspergillus
species are responsible for up to 80% of infections [22]. Overall,
the causal agents in invasive fungal sinusitis are the filamentous
fungi, including Apergillus, Mucor, Rhizozopus, Fusarium,
Pseudallescheria boydii, and the dematiaceous fungi such as
Alternaria, Bipolaris, Cladophialophora, and Curvularia spp.
[23].
Clinically invasive FRS is characterized by a painless, necrotic,
nasal septal ulcer (eschar), sinusitis, and rapid orbital and
intracranial spread, leading to death. Angioinvasion and
hematogenous dissemination are common. Microscopic
evaluation reveals hemorrhage, necrosis, and mixed acute
and chronic inflammation that may have a granulomatous
component. Given the urgent nature of acute fulminant
invasive FRS, intraoperative evaluation of frozen sections may
be requested, and antibiotic therapy should be initiated before
culture results are available [24].
Chronic invasive FRS is usually seen among diabetics. The
definition describes a sinusitis of at least more than twelve
weeks of duration compatible with radiologic findings and
histologic evidence of tissue invasion by fungal hyphal forms.
Histologically it’s characterized by vascular, bone and soft
tissue invasion; most commonly occurring is Aspergillus
fumigatus [24]. Fungal-specific cultures can grow a variety of
species including dematiaceous molds (Bipolaris, Curvularia,
and Alternaria) [21]. An important key that may play a role in
paranasal sinus aspergillosis are secretions of a toxic substance
by fungi that penetrates tissues under appropriate conditions
and induces tissue necrosis via an immune mechanism. Most
common symptoms described are diplopia, headache, loss and
impairment of smelling and nasal stuffiness. Fever is most often
absent [25].
Granulomatous FRS is a sub-type of chronic invasive FRS.
The time course is more than twelve weeks. This is described
more frequently in immunocompetent individuals. The cases
are more common in countries such as India, Pakistan and
the Sudan, but there are some cases reported in the United
States. The presentation is slow progression of the sinusitis with
headache and unilateral proptosis. Aspergillus fumigatus is the
responsible agent in most of the cases. The prognosis is better
than other invasive forms, and patients usually respond to
debridement, aeration, and antifungal therapy, with recurrence
being common [24].

Diagnosis of Rhinosinusitis
The diagnosis of invasive FRS is challenging. Often, cultures
from non-sterile fluid may be difficult to interpret and unable
to differentiate a pathogen from other flora. Invasive diagnostic
procedures relying on tissue biopsy or histopathological
specimens are preferred to make the diagnosis. The timing
between the diagnosis of FRS and the administration of
antifungal therapy will often influence the outcome of therapy.
This phase can be prolonged by diagnostic difficulties, including
diagnostic markers, such as fungal nucleic acids, antigens,
antibodies or assays for cell wall components. Detection of

fungal cell wall components is a rapid and attractive tool
for diagnosis. Beta-(1,3)-D-glucan (BDG) is one of those
components and is present in most pathogenic fungi such as
Candida spp., Fusarium spp., Aspergillus ssp., B. dermititidis,
and Pneumocystis [26]. Fungi for which BDG is of no value are
the Zygomycetes and cryptococci which have none to very low
concentrations of BDG in their cell wall, below that of detection
in human serum [27].
Galactomannan (GM) as another important cell wall
component of Aspergillus spp., but it does occur in some fungi
such as Fusarium spp. During invasive disease, as opposed
to colonization, the GM is released into the blood-stream
during intravascular hyphal growth. For this reason, in the
immunocompromised patient, the serum GM assay has shown
promise in the diagnosis of invasive aspergillosis. The association
of elevated serum GM levels are thus indicative (70-95%
specificity) of invasive aspergillosis. For immunocompromised
patients with high GM levels, we can tailor the diagnosis to
aspergillosis when used in combination with elevated C-reactive
protein and low procalcitonin levels [27]. Low procalcitonin
often rules-out bacterial infections, but it may still rise in
some yeast infections, but not so with aspergillosis. However,
false-positives for GM (45-55% specificity) are well noted, but
in conjunction with pathology and microbiology results, falsepositives can often be discounted.

Summary of Histopathologic
Microbiologic testing for FRS

and

Histopathology
Histopathology of FRS varies depending on whether it is noninvasive or invasive as discussed above. Montone, et al. [19]
recently classified the various histopathological criteria of FRS.
Histologic examination of saprophytic fungal infection reveals
inflamed and ulcerated sinonasal mucosa with the presence
of surface fungal organisms without tissue invasion. FB are
characterized by numerous fungal organisms embedded in
fibrinous and necrotic exudate with absent to minimal mucosal
inflammatory reaction [19, 28]. For AFRS, hematoxylin and
eosin (H&E)-stained histological sections show lamellated
mucinous material with the presence of eosinophils, eosinophilic
debris, Charcot-Leyden crystals and rare noninvasive fungal
hyphae [29]. Schneiderian mucosa reveals thickened basement
membrane with goblet cell hyperplasia, and numerous
inflammatory cells with prominent eosinophils. Invasive
FRS is classified into acute invasive FRS, chronic FRS and
chronic granulomatous FRS. In acute invasive FRS, histology
demonstrates rare inflammatory cells, with angioinvasion
of fungal forms causing thrombosis of the luminal surface,
often with infarction. H&E stains, Grocott’s methenamine
silver (GMS) and periodic acid-Schiff (PAS) stains provide
good contrast of the organisms which allows differentiation
from other material found in the vascular walls and lumens
that are often fibrin encompassed (Fig. 5). However, fungal
morphology is frequently elusive [19]. The histopathology of
chronic invasive granulomatous FRS is mainly characterized by
submucosal granulomatous inflammation, a small number of
fungi, fibrosis, and sometimes reactive epithelial hyperplasia. It
may also show florid granulomatous inflammation with tissue
invasion by fungal hyphae. Noncaseating granuloma with giant
cells and occasional central eosinophilic microgranulomata, as
well as fibrinoid necrosis, vasculitis, vascular proliferation, and
perivascular fibrosis are often seen [23]. In contrast, in cases
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Figure 5. Various stains used in Pathology. Left: H&E stain showing Aspergillus hyphae. Center: GMS stain showing a dematiaceous mold
with septate hyphae. Right: H&E lightly stained, showing dematiaceous mold with unstained brown hyphae (arrows).

of chronic invasive FRS, histopathology often shows more
numerous fungal organisms with sparse inflammatory infiltrate
and occasional angioinvasion and without the presence of
granulomas [19]. When dematiaceous fungi are involved, a
lightly stained, H&E stain can be performed; this will show the
brown colored hyphae of the fungal cell walls (Fig. 5, right)
when viewed by direct light microscopy.
Microbiology
Most serious fungal infections of the sinus are due to the
Zygomycetes, Mucor, Rhizopus, Rhizomucor, Absidia, and
Cunninghamella but reports exist of sinusitis also caused by
Apophysomyces, Syncephalstrum, Saksenaea, Cokeromyces,
Entomopthora, Conidiobolus, and Basidiobolus [30].
Aspergillus sp. are the second known leading cause of chronic
invasive sino-orbital and sino-pulmonary disease as well as
non-invasive FRS and AFRS [31]. In addition, several hyaline
molds, dematiaceous molds, Candida, and Basidiomycetes
may be involved in FRS of immunocompromised patients [32].
Therefore, the clinical microbiology of FRS is complex and
requires lengthy and laborious microbiological techniques to
recover and identify these microorganisms.
The diagnostic gold standard is to demonstrate the organism in
pathological stains followed by isolation of the mold in culture
of clinical specimens. Realistically this is not always the case.
In fact, only rarely is a clinical biopsy sent to microbiology for
recovery of the fungus in culture. Although pathologists can
accurately recognize fungi in clinical specimens, they are not so
familiar with morphological characteristics that they can identify
the organism to fungal family or genus. Although molecular
technology may change our ability to identify pathogens directly
from specimens, it is unlikely that this will occur any time soon.
Therefore, it is extremely important that microbiologists be
consulted when a specimen is submitted for a diagnosis of FRS.
The basic microbiology technique is the microscopic
examination of the fungal stain. Fungal stains commonly
used in microbiology are potassium hydroxide (10%, KOH),
Calcofluor white, lacto-phenol-cotton blue (LPCB), LPCB with
KOH, and to a lesser extent, PAS stain, Fontana-Masson, and
Giemsa stain. The Gram stain sometimes can reveal fungal
elements, but often the stain is over or under decolorized which
makes it difficult to interpret. Culture of the fungus is still the
primary means of recovery and identification. Polymerase chain
reaction (PCR), matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI TOF), and DNA
sequencing techniques have been applied directly to clinical
samples for the initial identification of fungi, however there is
still much to be accomplished in these areas before any of these
will become available as standardized, FDA approved techniques
in the clinical laboratory. Once the fungal isolate has been
recovered and grown in pure culture, both MALDI-TOF and DNA

sequencing can be primarily used for identification. Many clinical
laboratories now send isolates to reference laboratories for DNA
sequencing analysis which is extremely accurate, but also costly
(average of $300/isolate). Both technologies show great promise
for the future of clinical mycology.
The outcome of the microbiological workup is dependent upon
the quality and site and specimen collection. The swab is never
an optimal sample. Instead, surgically collected tissue including
exudates, necrotic areas, and tissue biopsies, are optimal.
Purulent drainage may be submitted to the laboratory, but due to
its polymicrobic nature, it seldom yields a significant pathogen.
The transportation of specimens to the laboratory should be
immediate and at room temperature. If a biopsy specimen is
sent and zygomycosis is suspected, the laboratory should be
alerted so that a touch-plate preparation can be performed
prior to grinding the tissue. The grinding process will often
destroy hyphae rendering the isolate uncultivable. Microbiology
laboratories often maintain many different culture media, both
selective and non-selective for the recovery of fungi [33]. Fungi
are grown on Sabouraud dextrose agar-Emmon’s modification
(SABDX), potato dextrose agar, potato flake agar, corn meal agar,
brain heart infusion agar (BHI) both with and without 5% sheep
blood and antibiotics, Littman oxgall agar, malt extract agar,
and Czapek’s agar. Cultures are incubated at 27°C, 30°C, 45°C,
and >50°C, to achieve optimal growth and culture morphology.
Increasing the spectrum of media planted and incubation
temperatures may increase the % recovery and lead to faster
identifications. Some fungi will develop full growth by 3 days, but
others may take up to 2 to 4 weeks to fully develop.
To date, due to cost containment measures, morphological
growth characteristics are still the most used method of fungal
identification. Both macroscopic and microscopic observations
are combined for final identification. Identification involves
recognition of sexual and asexual structures, color, size, shape,
ornamentation, septation, yeast forms, conidia production,
hyphae production, and spore germination. Several new texts are
available that describe and depict morphological characteristics
of the various clinically important fungi [33-36]. Morphological
identification requires extensive training and experience in the
field of mycology. The fungi are a diverse and complex group of
microorganisms that may have both sexual and asexual stages of
growth. For instance, there are 339 known species of Aspergillus
with nine teleomorph (sexual stage) genera. Recent phylogenic
studies indicate that this number may soon increase [37]. Of
these, there are only seven species that are commonly considered
clinically significant [14]. However, Chen et al., recently reported
that as many as 48 other uncommon Aspergillus species may be
pathogenic [38].
Many of the past clinically insignificant fungi have become
important considerations in FRS for the reasons discussed above.
The clinical laboratory formerly considered many fungal isolates
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Table 1. Common Antifungal Agents and Considerations when Treating Systemic Infections [49, 51-55]
Antifungal
Agent

Class

Mechanism of
Action

Normal Dose

Dosage
Form

Common Side Effects/
Specific Antifungal Considerations

Fluconazole

Triazole

Isavuconazole

Ergosterol
inhibitor

800 mg times 1 dose, then
400 mg daily

IV/Oral

Hepatic effects, QTc prolongation, skin
reactions, drug-drug interactions

Triazole

372 mg (isavuconazole 200
mg) every 8 hours for 6
doses, then 372 mg (200 mg
isavuconazole) daily

IV/Oral

Hepatic effects, GI effects, QTc
narrowing, CNS effects, skin reactions,
drug-drug interactions, high cost (no
generic available), risk of dosing errors
due to prodrug dosing

Itraconazole

Triazole

200 mg 3 times daily for
3 days, then 200 mg twice
daily

Oral

Hepatic effects, cardiomyopathy, GI
effects, QTc prolongation, skin reactions, type of formulation, drug-drug
interaction, patient tolerability, high
cost dependent on product

Posaconazole

Triazole

Suspension: 200 mg 3 times
daily with high fat meal
preferred

IV/Oral

Hepatic effects, QTc prolongation, CNS
effects, GI effects, skin reactions, type
of formulation, absorption, potential
for drug monitoring depending on
formulation, patient tolerability, avoid
IV use in renal insufficiency, high cost
(no generic available)

6 mg/kg every 12 hours for
2 doses then 4 mg/kg every
12 hours

IV/Oral

Hepatic effects, CNS effects, visual
disturbances, QTc prolongation, skin
reactions, drug-drug interactions,
avoid IV use in renal insufficiency

200 mg once, then 100 mg
daily

IV

Hepatic effects, cardiovascular effects,
insomnia, infusion reactions, only
available IV, high cost

IV/Delayed Release oral:
300 mg twice daily, then 300
mg daily
Voriconazole

Triazole

Anidulafungin

Echinocandin

Caspofungin

Echinocandin

70 mg once, then 50 mg
daily

IV

Hepatic effects, cardiovascular effects,
CNS effects, localized phlebitis, infusion reactions, only available IV, high
cost (no generic available)

Micafungin

Echinocandin

100-150 mg daily

IV

Hepatic effects, cardiovascular effects,
CNS effects, GI effects, hemolytic anemia/hemoglobinuria, only available IV,
high cost (no generic available)

Amphotericin B
(Liposomal)

Polyene

3-5 mg/kg/day

IV

Hepatic effects, nephrotoxicity, electrolyte abnormalities infusion reactions,
anemia, only available IV, patient
tolerability, high cost (no generic
available)

β-1,3-D-glucan
synthesis
inhibitor

Ergosterol
binding

GI=Gastrointestinal, CNS=Central Nervous System

as normal flora or contaminants and no further work-up was
done. Now with more immunocompromised patients, clinical
laboratories are reporting most isolates that occur in culture.
This has created an enigma in clinical medicine and one must be
current with the literature to determine if certain fungal isolates
are pathogenic. The greatest problem herein is that some fungal
names (genera and species) change with great frequency (every
fourth year), and a literature search for the isolate reported by the
laboratory may not yield adequate information to support serious
consideration. Secondly, the sexual and asexual stages of the fungi
have different names albeit they are the same microorganism.
As gene sequencing becomes widely available, this conundrum
of name changes due to re-classification of genera and species
based on DNA phylogeny is sure to increase in the upcoming
years. It is important that anytime an unusual fungus is reported
on a specimen, that a microbiologist be consulted as to determine
the clinical significance of the isolate. This includes yeast, yeastlike, and filamentous fungi. Genetic technology has revealed that
many fungi that were previously reported to genus and species
were indeed misidentified, leading mycologists to re-examine
past cases to determine the prevalence of certain fungi in certain
disease states [37-43].
Antifungal testing is a delicate, difficult, and often disappointing
endeavor. Although the Clinical and Laboratory Standards
Institute (CLSI) has taken great strides to publish both
techniques and interpretive standards for the susceptibility
testing of yeasts [44-47] and filamentous fungi [12], only a few
laboratories offer this technology. The difficulty with minimum
inhibitory concentration (MIC) interpretations is that there are
very few outcome studies performed whereby MIC standardized
susceptibilities were available on fungal isolates. This has limited

our efforts to establish reliable standard interpretive criteria and
much is still unresolved toward improvements this area.
Antibiotic Stewardship of FRS
Treatment of FRS can be very challenging. The patient may
have colonization or invasive infection with chronic or acute
FRS and may require aggressive surgical debridement with
antifungal treatment. Invasive FRS needing treatment is even
more complex. The host is typically immunocompromised, the
diagnosis elusive, and the identification prolonged. Because
of these facts, patients considered having invasive FRS, based
on risk factors and clinical presentation should be empirically
started on broad-spectrum intravenous (IV) antifungal
therapy, while identification is being done. In most cases, IV
amphotericin B products should be selected. Once identification
of the isolate is known, or if specific fungi can be ruled out,
then other antifungal agents could be considered to optimize
coverage, route of administration, toxicities, efficacy, or cost
[48-53].
Antifungal agents discussed here target the fungal cell membrane
(azoles and polyenes) or cell wall (echinocandins) [49]. There
are other sites targeted by antifungal agents, but these agents are
typically not used as monotherapy or in treatment of FRS. Table
1 includes commonly used systemic antifungal agents in the
hospital or outpatient setting. Some of these antifungal classes
share similar side effects or considerations, whereas others have
their own specific concerns. For example, all triazoles can affect
QTc measurements (all prolong, except isavuconazole, which
shortens) and have many drug-drug interactions. Whereas,
caution must be displayed when deciphering itraconazole
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capsules or tablets versus the suspension, since gastric acid
affects the absorption (capsules/tablets should be taken with
food, but the suspension is preferred and should be taken on an
empty stomach) [49, 50].

2. Sattler L, Sabou M, Ganeval-Stoll A, Dissaux C, Candolfi
E, Letscher-Bru V. Sinusitis caused by Scopulariopsis
brevicaulis: case report and review of the literature. Med
Mycol Case Reports. 2014; 5:24-27.

Good antifungal stewardship practices should be utilized when
possible. Once the fungus has been identified, the antifungal
may be narrowed. However, many considerations need to
be made and a multi-disciplinary approach should be used
for medication transitions. Susceptibilities should always be
checked since resistance by many fungi has been observed [49,
50, 56]. A clinical pharmacist, specifically trained in infectious
disease if available, can assist the team in selecting the best
option based on drug-drug interactions, common side effects or
toxicities, absorption concerns, dosing (using pharmacokinetic
and pharmacodynamics parameters), cost, and potentially
therapeutic antifungal monitoring goals. Good antifungal
stewardship with a multi-disciplinary approach is important
because it helps ensure an optimized antifungal regimen that is
both safe and efficacious.

3. Woudenberg JHC, Meijer M, Houbraken J, Samson
RA. Scopulariopsis and scopulariopsis-like species from
indoor environments. Stud Mycol. 2017 Sep; 88:1-35.

Summary
We presented four human case reports of fungi that cause
FRS. All four cases originated at our Veterans’ hospital within
a two-year period. The diagnosis and therapy in all four
cases required a full spectrum of professional contributions:
Infectious Disease Specialists, Pathologists, Microbiologist, and
Clinical Pharmacists. It is important for ENT specialists and
other disciplines of medicine to recognize that the fungi of FRS
are complex microorganisms that encompass a wide variety of
species (pathogenic and formerly non-pathogenic), and they are
very difficult to recognize and identify. The current technology
to identify fungi is lengthy, and optimum patient therapy is
often delayed. Likewise, the host range of immunocompetent
and immunocompromised individuals further complicates the
clinical presentation of their various disease states. Antifungal
therapy for FRS is vague in the literature, thus antimicrobial
stewardship is important for patient care. The toxicity of
antifungals is of significant concern and requires the skills of
both Infectious Disease specialists and Pharmacists to establish
the best dosing regimen. We briefly reviewed and summarized
the contributions of many other authors to show the extensive
amount of work already done in this area. There is yet much to
be accomplished before FRS can be fully appreciated as a cause
of significant morbidity and mortality. We attribute our success
in this area to the willingness of our professional staff to work
closely together and overcome the many challenges that are
faced when a patient presents with FRS.
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